We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH – Research Report) and Eli ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease and ulcerative colitis, is the company's latest step into the treatment of ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.

Eli Lilly's Q4 FY24 guidance adjustment is due to supply chain factors, not demand, creating an attractive buying opportunity with a 'Buy' rating. Despite a modest 0.6% revenue reduction ...